688247 宣泰医药
已收盘 02-27 15:00:00
资讯
新帖
简况
宣泰医药2024年业绩快报:归母净利润1.28亿元
财中社 · 02-26 08:38
宣泰医药2024年业绩快报:归母净利润1.28亿元
宣泰医药最新公告:2024年净利润为1.28亿元 同比增长109.97%
证券之星 · 02-26 08:25
宣泰医药最新公告:2024年净利润为1.28亿元 同比增长109.97%
宣泰医药发布2024年度业绩快报,盈利1.282亿元
证券之星 · 02-26 08:25
宣泰医药发布2024年度业绩快报,盈利1.282亿元
宣泰医药:2024年净利润为1.28亿元 同比增长109.97%
美港电讯 · 02-26 07:39
宣泰医药:2024年净利润为1.28亿元 同比增长109.97%
宣泰医药:2024年净利润1.28亿元 同比上升109.97%
格隆汇资讯 · 02-26 07:35
宣泰医药:2024年净利润1.28亿元 同比上升109.97%
宣泰医药(688247.SH)2024年度净利润1.28亿元 同比上升109.97%
智通财经 · 02-26 07:34
宣泰医药(688247.SH)2024年度净利润1.28亿元 同比上升109.97%
每周股票复盘:宣泰医药(688247)完成股份回购并公布2025年度日常关联交易预计
证券之星 · 02-22
每周股票复盘:宣泰医药(688247)完成股份回购并公布2025年度日常关联交易预计
AI+医疗行业深度:AI+医药:势不可挡,未来已至
中邮证券 · 02-19
AI+医疗行业深度:AI+医药:势不可挡,未来已至
宣泰医药:累计回购约434万股
每日经济新闻 · 02-18
宣泰医药:累计回购约434万股
宣泰医药涨5.27% 粤民投入主成大生物
智选洞察 · 02-14
宣泰医药涨5.27% 粤民投入主成大生物
医药行业:从摩根大通医疗健康大会看生物创新药管线,关注ADC、双特异性抗体、细胞与基因治疗
研报虎 · 02-11
医药行业:从摩根大通医疗健康大会看生物创新药管线,关注ADC、双特异性抗体、细胞与基因治疗
医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE
太平洋证券股份... · 02-10
医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE
部分集采药陷质量争议,医保药监:将持续加强药品质量监管,支持更大范围考察药品疗效
时代财经 · 02-10
部分集采药陷质量争议,医保药监:将持续加强药品质量监管,支持更大范围考察药品疗效
国家医保局:把较高质量风险产品排除在集采之外
智通财经 · 02-10
国家医保局:把较高质量风险产品排除在集采之外
“血压不降、麻药不睡、泻药不泻”,官方最新回应!
南方都市报 · 02-09
“血压不降、麻药不睡、泻药不泻”,官方最新回应!
2月6日宣泰医药发布公告,股东减持57.52万股
证券之星 · 02-06
2月6日宣泰医药发布公告,股东减持57.52万股
宣泰医药(688247.SH):栖和创业合计减持57.52万股
智通财经 · 02-06
宣泰医药(688247.SH):栖和创业合计减持57.52万股
宣泰医药股东减持计划启动 持股比例降至7.9902%
财中社 · 02-06
宣泰医药股东减持计划启动 持股比例降至7.9902%
宣泰医药:已回购0.96%公司股份 支付资金总额约3612.60万元
中国财富通 · 02-05
宣泰医药:已回购0.96%公司股份 支付资金总额约3612.60万元
宣泰医药:累计回购约434万股
每日经济新闻 · 02-05
宣泰医药:累计回购约434万股
加载更多
公司概况
公司名称:
上海宣泰医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2022-08-25
主营业务:
上海宣泰医药科技股份有限公司的主营业务是高端仿制药的研发、生产和销售以及CRO服务。公司的主要产品是高端仿制药、CRO服务。公司先后获得“上海市专利工作试点企业”、“上海市‘专精特新’中小企业”、“第四届上海知识产权创新奖专利二等奖”等荣誉。
发行价格:
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":11.05,"timestamp":1740639600000,"preClose":10.68,"halted":0,"volume":9614279,"delay":0,"changeRate":0.0346,"floatShares":142000000,"shares":453000000,"eps":0.2418,"marketStatus":"已收盘","change":0.37,"latestTime":"02-27 15:00:00","open":10.87,"high":11.15,"low":10.7,"amount":105000000,"amplitude":0.0421,"askPrice":11.05,"askSize":14,"bidPrice":11.04,"bidSize":97,"shortable":0,"etf":0,"ttmEps":0.2418,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1740706200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.68,"symbolType":"stock_kcb","openAndCloseTimeList":[[1740619800000,1740627000000],[1740632400000,1740639600000]],"highLimit":11.75,"lowLimit":9.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":4.05,"roa":"--","peRate":45.698925,"roe":"7.58%","epsLYR":0.13,"committee":-0.286965,"marketValue":5009000000,"turnoverRate":0.0676,"status":0,"afterMarket":{"amount":0,"volume":0,"close":11.05,"buyVolume":0,"sellVolume":0,"time":1740641638029,"indexStatus":"已收盘 02-27 15:30:00","preClose":10.68},"floatMarketCap":1573000000},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2514895818","title":"宣泰医药2024年业绩快报:归母净利润1.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895818","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514895818?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:38","pubTimestamp":1740559080,"startTime":"0","endTime":"0","summary":"2月26日,宣泰医药发布公告,2024年度业绩快报显示,公司实现营业总收入5.13亿元,同比增长70.97%;归母净利润为1.28亿元,同比上升109.97%。报告期内,公司深耕主业,产品销售收入及权益分成收入显著增长,同时随着CRO/CMO客户产品获批上市,CMO收入增长明显。基本每股收益同比上升115.38%,加权平均净资产收益率同比增加5.28个百分点,主要系归母净利润大幅增加所致。2024年前三季度,宣泰医药实现收入3.63亿元,归母净利润9257万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261641499630f8db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261641499630f8db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247"],"gpt_icon":0},{"id":"2514883911","title":"宣泰医药最新公告:2024年净利润为1.28亿元 同比增长109.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514883911?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:25","pubTimestamp":1740558353,"startTime":"0","endTime":"0","summary":"宣泰医药公告称,营业总收入为5.13亿元,同比增长70.97%;归属于母公司所有者的净利润为1.28亿元,同比增长109.97%。主要原因包括产品销售收入及权益分成收入显著增长,以及CMO收入增长明显。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600028109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247"],"gpt_icon":0},{"id":"2514883924","title":"宣泰医药发布2024年度业绩快报,盈利1.282亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514883924?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:25","pubTimestamp":1740558339,"startTime":"0","endTime":"0","summary":"证券之星消息,宣泰医药近日即将发布2024年年报,根据2月26日发布的业绩快报,归属净利润盈利1.282亿元,同比增长109.97%。报告期内,公司深耕主业,持续加强产品国内外销售,产品销售收入及权益分成收入显著增长;同时随着 CRO/CMO 客户产品获批上市,商业化生产供应增加,CMO 收入增长明显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022600028130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2514004948","title":"宣泰医药:2024年净利润为1.28亿元 同比增长109.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004948","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514004948?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:39","pubTimestamp":1740555567,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2514002255","title":"宣泰医药:2024年净利润1.28亿元 同比上升109.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514002255","media":"格隆汇资讯","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514002255?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:35","pubTimestamp":1740555339,"startTime":"0","endTime":"0","summary":"格隆汇2月26日丨宣泰医药公布2024年度业绩快报,本报告期,公司实现营业总收入51,269.10万元,同比增长70.97%;归属于母公司所有者的净利润为12,823.46万元,同比上升109.97%,归属于母公司所有者的扣除非经常性损益的净利润为11,435.84万元,同比上升140.89%。报告期内,公司深耕主业,持续加强产品国内外销售,产品销售收入及权益分成收入显著增长;同时随着CRO/CMO客户产品获批上市,商业化生产供应增加,CMO收入增长明显。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261535489630dfe0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261535489630dfe0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"宣泰医药:2024年净利润1.28亿元 同比上升109.97%","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247"],"gpt_icon":0},{"id":"2514004987","title":"宣泰医药(688247.SH)2024年度净利润1.28亿元 同比上升109.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514004987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514004987?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:34","pubTimestamp":1740555263,"startTime":"0","endTime":"0","summary":"智通财经APP讯,宣泰医药(688247.SH)发布2024年度业绩快报,报告期,公司实现营业总收入5.13亿元,同比增长70.97%;归属于母公司所有者的净利润为1.28亿元,同比上升109.97%。报告期内,公司深耕主业,持续加强产品国内外销售,产品销售收入及权益分成收入显著增长;同时随着CRO/CMO客户产品获批上市,商业化生产供应增加,CMO收入增长明显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247"],"gpt_icon":0},{"id":"2513424729","title":"每周股票复盘:宣泰医药(688247)完成股份回购并公布2025年度日常关联交易预计","url":"https://stock-news.laohu8.com/highlight/detail?id=2513424729","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513424729?lang=zh_cn&edition=full","pubTime":"2025-02-22 10:03","pubTimestamp":1740189789,"startTime":"0","endTime":"0","summary":"第二届监事会第十次会议决议公告上海宣泰医药科技股份有限公司第二届监事会第十次会议于2025年2月19日以通讯方式召开,会议审议通过了《关于公司2025年度日常关联交易预计的议案》,表决结果为同意3票,反对0票,弃权0票。关于2025年度日常关联交易预计的公告上海宣泰医药科技股份有限公司预计2025年度日常关联交易总额为1,252万元,主要包括提供技术服务、产品生产和销售、以及金融服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022200010558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2512212496","title":"AI+医疗行业深度:AI+医药:势不可挡,未来已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2512212496","media":"中邮证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512212496?lang=zh_cn&edition=full","pubTime":"2025-02-19 15:04","pubTimestamp":1739948697,"startTime":"0","endTime":"0","summary":"投资要点“AI+医疗”解决方案全球市场有望突破千亿美元,有望进入到商业化加速阶段。“AI+医疗”行业人工智能解决方案的全球市场规模预计将由2022年的137亿美元增至2030年的1,553亿美元,CAGR为35.5%,行业存在爆发式增长机会。政策面上,国内宏观政策利好AI制药,医疗AI三类证审批加速。我们认为“AI+医疗”有望应用于药物研发、癌症诊断、医学影像、手术机器人等领域,行业或迎来巨变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219150422a24b831f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219150422a24b831f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","688356","BK0239","603520","688221","688189","159891","BK0028","688062","601089","600200","600488","600624","600513","603811","688235","688513","688428","688578","688076","688602","688758","688166","BK0185","BK0188","688690","600216","603676","603351","BK0010","688247","603168","600812","603367","603538","605116","688266","688799","603669","600062","600380","688382","688505","688321","688117","600196","688197","600851","688553","159938","688566","603207","600276","600420","688373","688658","BK0175","603229","605507","600664","688091","688192","600613","600079","600789","600774","605177","688302","688176"],"gpt_icon":0},{"id":"2512213089","title":"宣泰医药:累计回购约434万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512213089","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512213089?lang=zh_cn&edition=full","pubTime":"2025-02-18 18:19","pubTimestamp":1739873953,"startTime":"0","endTime":"0","summary":"每经AI快讯,宣泰医药 2月18日晚间发布公告称,截至2025年2月18日,本次股份回购实施期限届满,公司已完成本次回购。2023年1至12月份,宣泰医药的营业收入构成为:医药制造业占比99.84%。宣泰医药的董事长是叶峻,男,52岁,学历背景为硕士;总经理是郭明洁,男,51岁,学历背景为硕士。截至发稿,宣泰医药市值为48亿元。道达号“个股趋势”提醒:1. 宣泰医药近30日内北向资金持股量未发生变化;2. 近30日内无机构对宣泰医药进行调研。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021818203996275c1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021818203996275c1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2511685539","title":"宣泰医药涨5.27% 粤民投入主成大生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2511685539","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511685539?lang=zh_cn&edition=full","pubTime":"2025-02-14 09:46","pubTimestamp":1739497584,"startTime":"0","endTime":"0","summary":"02月14日,宣泰医药股价大幅上涨,截至09点46分,宣泰医药上涨5.27%,报10.79元/股,创近1个月新高,成交2293万元,换手率1.54%,振幅4.98%。蛰伏五年,粤民投决定正式入主辽宁成大和成大生物两家上市公司。粤民投通过其全资子公司韶关高腾实现对辽宁成大经营管理产生重大影响,从而间接控制成大生物54.67%股权。最新财报显示,今年三季报,宣泰医药实现营业收入3.63亿元,同比增长69.95%,净利润为9,257.30万元,同比增长110.00%,基本每股收益为0.21元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140947589622521c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140947589622521c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688739","BK0239","688247"],"gpt_icon":0},{"id":"2510827757","title":"医药行业:从摩根大通医疗健康大会看生物创新药管线,关注ADC、双特异性抗体、细胞与基因治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2510827757","media":"研报虎","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510827757?lang=zh_cn&edition=full","pubTime":"2025-02-11 13:59","pubTimestamp":1739253565,"startTime":"0","endTime":"0","summary":"2025年第四十三届摩根大通医疗健康年会盛大召开。我们从本次会议的热点一窥行业创新升级的重点方向,关注抗体偶联药物、双特异性抗体、细胞与基因治疗等生物创新药领域的最新进展。2025JPM大会展示的ADC药物多达数十款,基本为第三代产品,面向肺癌、乳腺癌、肺癌等高发实体瘤,涌现出一大批创新前沿的生物技术公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211140710abca815b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600774","688266","600488","600521","688553","600624","688356","688690","BK0188","600216","688189","603520","600613","BK0239","688799","688176","688117","688247","BK0060","688513","605177","BK0187","600062","603351","BK0012","605116","603669","688302","600380","603207","BK0175","159760","603538","603168","688658","688602","688235","688578","603229","601089","600196","603676","600267","603811","688321","BK0196","688197","600513","600664","688506","600276","BK0028","600420","BK0183","600079","600200","688505","688566","BK0096","688428","688373","688221","605507","159992","603367","603707"],"gpt_icon":0},{"id":"2510277958","title":"医药行业周报:诺华三抗新药PIT565在华再获批临床 用于SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2510277958","media":"太平洋证券股份...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510277958?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:00","pubTimestamp":1739203200,"startTime":"0","endTime":"0","summary":"行业要闻:近日,中国国家药监局药品审评中心官网公示,诺华申报的1 类新药PIT565 获得一项新的临床试验默示许可,拟开发治疗系统性红斑狼疮。PIT565 是一款抗CD3/CD19/CD2 的三特异性抗体,可以靶向恶性B 细胞上的CD19,同时可与T 细胞上的CD3和CD2结合。与CD3 双特异性相比,通过PIT565共刺激CD2 可能会克服T 细胞衰竭,增加患者反应的深度和持续时间,该药此前在华获批针对B 细胞恶性肿瘤的IND。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211120756961eb981&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211120756961eb981&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603669","600276","603811","688029","603367","688358","603309","688192","600789","688581","688617","601089","688266","688247","688189","603707","605507","688176","600624","600420","605177","688091","603880","688236","603387","688575","688338","688758","603987","600851","603676","688677","688767","BK0060","688067","603520","BK0188","605116","688613","688690","688221","688062","600196","688076","688373","688602","600488","600200","688166","688273","603658","688085","600216","688799","688553","688321","688151","688217","BK0028","600774","688212","688197","600807","688506","688578","688428","688198","688298","688626","688235","688580","BK0239","603205","688026","688161","603229","605369","600062","688566","600380","688389","600513","688399","600079","603351","688139","603538","603222","688505","688108","688606","600521","600267","688016","688382","688075","603976","600529","600055","688607","688271","688468","600645","600664","688117","603301","688513","603207","688576","600812","688317","688658","600587","603168","688050","688302","600613","688356","688013","688193","688426"],"gpt_icon":0},{"id":"2510887125","title":"部分集采药陷质量争议,医保药监:将持续加强药品质量监管,支持更大范围考察药品疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2510887125","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510887125?lang=zh_cn&edition=full","pubTime":"2025-02-10 12:39","pubTimestamp":1739162344,"startTime":"0","endTime":"0","summary":"尤其是药品质量方面,上述相关部门指出,药品质量安全不仅是企业的生命线,也是监管部门的底线。长期以来,药监部门对药品质量、尤其对集采中选药品质量严格监管,坚持“全覆盖”“零容忍”。国家医保部门、药监部门对媒体称。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210123918961d7421&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210123918961d7421&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","688356","BK0239","603520","688221","688189","688062","600200","600624","600513","688513","688428","688758","688076","688166","BK0188","603351","688247","603168","600812","603669","603707","688505","600267","688321","600196","688197","688553","688566","BK0168","688373","688658","603229","600664","688091","688192","BK0046","600613","600789","600774","688302","688176"],"gpt_icon":0},{"id":"2510488390","title":"国家医保局:把较高质量风险产品排除在集采之外","url":"https://stock-news.laohu8.com/highlight/detail?id=2510488390","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510488390?lang=zh_cn&edition=full","pubTime":"2025-02-10 10:43","pubTimestamp":1739155385,"startTime":"0","endTime":"0","summary":"2018年以来的持续实践,既让集采政策和集采药品得到了临床检验,也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面,国家医保局表示,将广泛了解药品接受日常监管情况,把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种,提前进行强竞争预警,提示企业慎重决策,科学投标,理性报价。对偏离度高的最低报价予以重点关注,并请企业及时公开回应有关关切。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","688505","688091","603229","600079","LU1064131003.USD","688176","688247","603676","688578","688690","603811","600380","603168","688373","603207","605507","600062","600851","600216","600521","603351","688302","688758","BK0183","603520","688553","600267","600613","BK0012","LU1064130708.USD","600624","600774","688602","688506","LU0405327494.USD","BK0060","BK0196","688221","LU2328871848.SGD","600789","688321","688266","605177","605116","603669","601089","LU0405327148.USD","688356","600276","600200","600196","600812","688189","688566","BK0188","600420","688192","BK0239","688513","688382","600664","LU2488822045.USD","688799","LU1328615791.USD","600513","603707","688117","603367","600488","688197","LU1969619763.USD","688076","688658","688166","LU2148510915.USD","603538","BK0028","688428","688062"],"gpt_icon":0},{"id":"2510188717","title":"“血压不降、麻药不睡、泻药不泻”,官方最新回应!","url":"https://stock-news.laohu8.com/highlight/detail?id=2510188717","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510188717?lang=zh_cn&edition=full","pubTime":"2025-02-09 16:37","pubTimestamp":1739090269,"startTime":"0","endTime":"0","summary":"据国家医保局今天下午消息:今年1月,有专家认为某些集采药品可能存在“血压不降、麻药不睡、泻药不泻”质量风险。瑞金医院及其他几家医院均反映,未收到临床一线关于“泻药不泻”的相关反馈。总的来看,此次关于“血压不降、麻药不睡、泻药不泻”等说法,多来自他人转述和主观感受。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209164530abc8199a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209164530abc8199a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","603207","600267","603229","603707","688197","688302","688356","688117","688189","600664","688428","600196","600774","688690","688505","688758","600513","688321","600200","600812","600488","600521","688192","BK0239","688513","688062","688553","688221","688076","603168","688566","688166","603520","605177","600624","603351","600613","600789","688091","688658","688247","603676","603669","688176"],"gpt_icon":0},{"id":"2509622864","title":"2月6日宣泰医药发布公告,股东减持57.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509622864","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509622864?lang=zh_cn&edition=full","pubTime":"2025-02-06 18:01","pubTimestamp":1738836071,"startTime":"0","endTime":"0","summary":"证券之星消息,2月6日宣泰医药发布公告《宣泰医药:关于持股5%以上股东权益变动触及1%的提示性公告》,其股东南京市栖和创业投资合伙企业(有限合伙)于2025年1月21日至2025年2月5日间合计减持57.52万股,占公司目前总股本的0.1269%,变动期间该股股价上涨0.49%,截止2月5日收盘报10.19元。股东增减持详情见下表:根据宣泰医药2024年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020600031027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"gpt_icon":0},{"id":"2509046244","title":"宣泰医药(688247.SH):栖和创业合计减持57.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509046244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509046244?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:16","pubTimestamp":1738833367,"startTime":"0","endTime":"0","summary":"智通财经APP讯,宣泰医药(688247.SH)发布公告,股东栖和创业于2025年1月21日至2025年2月5日合计减持公司股份57.52万股,占总股本0.1269%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161022","688247","BK0239"],"gpt_icon":0},{"id":"2509724719","title":"宣泰医药股东减持计划启动 持股比例降至7.9902%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509724719","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509724719?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:05","pubTimestamp":1738832705,"startTime":"0","endTime":"0","summary":"此次减持后,栖和创业持有公司股份由3680万股减少至3622万股,占公司总股本的比例由8.1171%减少至7.9902%。此次权益变动中,栖和创业通过集中竞价交易在2025年1月21日至2025年2月5日期间减持了57.5万股,变动比例为0.1269%。2024年前三季度,宣泰医药实现收入3.63亿元,归母净利润9257万元。文章来源:财中社宣泰医药股东减持计划启动 持股比例降至7.9902%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206172916a23b7850&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206172916a23b7850&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2509083154","title":"宣泰医药:已回购0.96%公司股份 支付资金总额约3612.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509083154","media":"中国财富通","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509083154?lang=zh_cn&edition=full","pubTime":"2025-02-05 18:00","pubTimestamp":1738749602,"startTime":"0","endTime":"0","summary":"中国财富通2月5日 - 宣泰医药(688247)公告称,截至2025年1月31日,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份4,336,109股,占公司总股本的比例为0.96%,购买的最高价为8.98元/股,最低价为7.40元/股,支付的资金总额为人民币36,126,025.26元(不含印花税、交易佣金等交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=VnmnGdQS%2Bps%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688247","BK0239"],"gpt_icon":0},{"id":"2509475481","title":"宣泰医药:累计回购约434万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509475481","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509475481?lang=zh_cn&edition=full","pubTime":"2025-02-05 15:49","pubTimestamp":1738741767,"startTime":"0","endTime":"0","summary":"每经AI快讯,宣泰医药2月5日晚间发布公告称,截至2025年1月31日,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份约434万股,占公司总股本约4.53亿股的比例为0.96%,购买的最高价为8.98元/股,最低价为7.4元/股,支付的资金总额为人民币约3613万元。宣泰医药的董事长是叶峻,男,52岁,学历背景为硕士;总经理是郭明洁,男,51岁,学历背景为硕士。每经头条(nbdtoutiao)——“没想到爆成这样”!刚刚,《哪咤2》票房破50亿元,从业者惊叹:前所未见的盛况!受冲击最大竟是《熊出没》(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502051550499618a829&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502051550499618a829&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688247","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1740701132098,"stockEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.0865},{"period":"3month","weight":0.0175},{"period":"6month","weight":0.3396},{"period":"1year","weight":0.3797},{"period":"ytd","weight":0.0984}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0423},{"period":"3month","weight":0.0185},{"period":"6month","weight":0.192},{"period":"1year","weight":0.1454},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6986人(较上一季度减少0.11%)","perCapita":"20372股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药的研发、生产和销售以及CRO服务。公司的主要产品是高端仿制药、CRO服务。公司先后获得“上海市专利工作试点企业”、“上海市‘专精特新’中小企业”、“第四届上海知识产权创新奖专利二等奖”等荣誉。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.2","shortVersion":"4.31.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}